A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity

Canadian Journal of Physiology and Pharmacology

Volumn 87, Issue 10, 2009, Pages 756-763

  Lehenbauer Ludke, Ana R ^a   Al Shudiefat, Abd Al Rahman S ^a   Dhingra, Sanjiv ^a   Jassal, Davinder S ^a   Singal, Pawan K ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antioxidants; Congestive heart failure; Oxidative stress

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PROBUCOL; PROCARBAZINE; RAZOXANE; TRASTUZUMAB; TROPONIN; VINCRISTINE;

ADULT; ANAMNESIS; ANGIOGRAPHY; CARDIOMYOPATHY; CARDIOTOXICITY; CASE REPORT; DRUG MECHANISM; ELECTROCARDIOGRAPHY; HEART ASSIST DEVICE; HEART MUSCLE BIOPSY; HEART PROTECTION; HUMAN; MULTIGATED RADIONUCLIDE ANGIOGRAPHY; NONHUMAN; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RAT; REVIEW; SCINTIGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; DOXORUBICIN; HEART DISEASES; HUMANS; PROGNOSIS; RATS; RISK FACTORS;

EID: 70449111766     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y09-059     Document Type: Review

References (76)

1. Abraham, S.A., Waterhouse, D.N., Mayer, L.D., Cullis, P.R., Madden, T.D., and Bally, M.B. 2005. The liposomal formulation of doxorubicin. Methods Enzymol. 391: 71-97. doi:10.1016/S0076-6879(05)91004-91005 PMID:15721375.
2. Agarwala, S., Kumar, R., Bhatnagar, V., Bajpai, M., Gupta, D.K., and Mitra, D.K. 2000. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J. Pediatr. Surg. 35(12): 1786-1789. doi:10.1053/jpsu.2000.19253.PMID:11101737.
3. Al-Mallah, M.H., Tleyjeh, I.M., Abdel-Latif, A.A., and Weaver, W.D. 2006. Angiotensin-Converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 47(8): 1576-1583. doi:10.1016/j.jacc.2005.11.073. PMID:16630993.
4. Allen, A. 1992. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol. 19(5): 529-542. PMID:1411651.
5. Arico, M., Nespoli, L., Pedroni, E., Bonetti, F., Vigano, M., and Burgio, G.R. 1988. Heart transplantation in a child with doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 319(20): 1353. PMID:3054552.
6. Ballou, B., Lagerholm, B.C., Ernst, L.A., Bruchez, M.P., and Waggoner, A.S. 2004. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 15(1): 79-86. doi:10.1021/bc034153y. PMID:14733586.
7. Batist, G., Ramakrishnan, G., Rao, C.S., Chandrasekharan, A., Gutheil, J., Guthrie, T., et al. 2001. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19(5): 1444-1454. PMID:11230490.
8. Bhattacharya, S., and Lahiri. A. 1991. Clinical role of indium-111 antimyosin imaging. Eur. J. Nucl. Med. 18(11): 889-895. doi:10.1007/BF02258455. PMID:1752262.
9. Biganzoli, L., Cufer, T., Bruning, P., Coleman, R.E., Duchateau, L., Rapoport, B., et al. 2003. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients: results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer, 97(1): 40-45. doi:10.1002/cncr.10914. PMID:12491503. (Pubitemid 36033861)
10. Blankenberg, F.G., Katsikis, P.D., Tait, J.F., Davis, R.E., Naumovski, L., Ohtsuki, K., et al. 1998. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. U.S.A. 95(11): 6349-6354. doi:10.1073/pnas.95.11.6349. PMID:9600968.
11. Bosch, T.M. 2008. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol. Cell. Biol. 448: 63-76. doi:10.1007/978-1-59745-205-2-5.
12. Bristow, M.R., Mason, J.W., Billingham, M.E., and Daniels, J.R. 1981. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am. Heart J. 102(4): 709-718. doi:10.1016/0002-8703(81)90096-X. PMID:7282516.
13. Chambers, J.T., Chambers, S.K., Kohorn, E.I., Carcangiu, M.L., and Schwartz, P.E. 1996. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol. Oncol. 60(3): 438-442. doi:10.1006/gyno.1996.0070. PMID:8774654.
14. Çorapçioglu, F., Sarper, N., Berk, F., Sahin, T., Zengin, E., and Demir, H. 2006. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr. Hematol. Oncol. 23(1): 71-80. doi:10.1080/08880010500313603. PMID:16326416.
15. Cvetković, R.S., and Scott, L.J. 2005. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 65(7): 1005-1024. PMID:15892593.
16. Doroshow, J.H. 1983a. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 43(10): 4543-4S51. PMID: 6309369.
17. Doroshow, J.H. 1983b. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43(2): 460-472. PMID:6293697.
18. Doroshow, J.H., Locker, G.Y., and Myers, C.E. 1980. Enzymatic defences of the mouse heart against reactive oxygen metabolites. J. Clin. Invest. 65(1): 128-135. doi:10.1172/JCI109642. PMID:7350193.
19. Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kantoff, P.W., et al. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 103(16): 6315-6320. doi:10.1073/pnas.0601755103. PMID:16606824.
20. Feng, S.S., and Chien, S. 2003. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 58(18): 4087-4114. doi:10.1016/S0009-2509(03)00234-3.
21. Ganz, W.I., Sridhar, K.S., Ganz, S.S., Gonzalez, R., Chakko, S., and Serafini, A. 1996. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology, 53(6): 461-470. doi:10.1159/000227621. PMID:8960141. (Pubitemid 26388387)
22. Gewirtz, D.A. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57(7): 727-741. doi:10.1016/S0006-2952(98) 00307-4. PMID:10075079.
23. Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., et al. 1995. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 13(11): 2688-2699. PMID:7595726.
24. Gilladoga, A.C., Manuel, C., Tan, C.T., Wollner, N., Sternberg, S.S., and Murphy, M.L. 1976. The cardiotoxicity of adriamycin and daunomycin in children. Cancer, 37(2 Suppl): 1070-1078. doi:10.1002/1097-0142(197602)37:2+〈1070:: AID-CNCR2820370814〉3.0.CO;2-6. PMID:1253124.
25. Gschwind, A., Fischer, O.M., and Ullrich, A. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer, 4(5): 361-370. doi:10.1038/nrc1360. PMID:15122207.
26. Gupta, M., Steinherz, P.G., Cheung, N.K., and Steinherz, L. 2003. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med. Pediatr. Oncol. 40(6): 343-347. doi:10.1002/mpo.10298. PMID:12692800.
27. Hensley, M.L., Hagerty, K.L., Kewalramani, T., Green, D.M., Meropol, N.J., Wasserman, T.H., et al. 2009. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27(1): 127-145. doi: 10.1200/JCO.2008.17.2627. PMID:19018081.
28. Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein. F., Kjekshus, J., et al. 2000. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HE). JAMA. 283(10): 1295-1302. doi:10.1001/jama.283.10.1295. PMID:10714728.
29. Hunt, S.A. 2005. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46(6): e1-e82. doi:10.1016/j.jacc.2005.08.022. PMID:16168273.
30. Iliskovic, N., and Singal, P.K. 1997. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am. J. Pathol. 150(2): 727-734. PMID:9033285.
31. Iliskovic, N., Panagia, V., Slezák, J., Kumar, D., Li, T., and Singal, P.K. 1997. Adriamycin depresses in vivo and in vitro phosphatidylethanolamine N-methylation in rat heart sarcolemma. Mol. Cell. Biochem. 176(1-2): 235-240. doi:10.1023/A:1006805229758. PMID:9406167.
32. Injac, R., and Strukelj, B. 2008. Recent advances in protection against doxorabicin-induced toxicity. Technol. Cancer Res. Treat. 7(6): 497-516. PMID:19044329.
33. Italia, J.L., Bhatt, D.K., Bhardwaj, V., Tikoo, K., and Kumar, M.N. 2007. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Release, 119(2): 197-206. doi:10.1016/j.jconrel.2007.02.004. PMID:17399839.
34. Jassal, D.S., Othman, R.A., Ahmadie, R., Fang, T., Zieroth, S., Fischer, G., and Moghadasian, M.H. 2009. The role of tissue Doppler imaging in the noninvasive detection of chronic rejection after heterotopic cardiac transplantation in rats. Echocardiography, 26(1): 37-43. doi:10.1111/j.1540- 8175.2008.00751.x. PMID:19125807.
35. Johnston, S.R.D., and Gore, M.E. 2001. Caelyx: phase II studies in ovarian cancer. Eur. J. Cancer, 37(Suppl 9): S8-S14. doi:10.1016/S0959-8049(01) 00329-X. PMID:11741768.
36. Kalaria, D.R., Sharma, G., Beniwal, V., and Ravi Kumar, M.N. 2009. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm. Res. 26(3): 492-501. doi:10.1007/s11095-008-9763-4. PMID:18998202.
37. Kim, D., Park, S., Lee, J.H., Jeong, Y.Y., and Jon, S. 2007. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J. Am. Chem. Soc. 129(24): 7661-7665. doi:10.1021/ja071471p. PMID:17530850.
38. Kumar, D., Lou, H., and Singal, P.K. 2002. Oxidative stress and apoptosis in heart dysfunction. Herz, 27(7): 662-668. doi:10.1007/s00059-002-2430-3. PMID:12439637. (Pubitemid 35415251)
39. Lefrak, E.A., Pitha, J., Rosenheim, S., and Gottlieb, J.A. 1973. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32(2): 302-314. doi:10.1002/1097-0142(197308)32:2〈302::AID-CNCR2820320205〉3.0.CO;2-2. PMID4353012.
40. Li, T., Danelisen, I., Belló-Klein, A., and Singal, P.K. 2000. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc. Res. 46(3): 523-530. doi:10.1016/S0008- 6363(00)00039-0. PMID:10912462.
41. Links, M., and Lewis, C. 1999. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs, 57(3): 293-308. doi:10.2165/00003495-199957030-00003. PMID:10193684. (Pubitemid 29137477)
42. Lipshultz, S.E., Sanders, S.P., Goorin, A.M., Krischer, J.P., Sallan, S.E., and Colan, S.D. 1994. Monitoring for anthracycline cardiotoxicity. Pediatrics, 93(3): 433-437. PMID:7818624.
43. Liu, Z., Davis, C., Cai, W., He, L., Chen, X., and Dai, H. 2008. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 105(5): 1410-1415. doi:10.1073/pnas.0707654105. PMID:18230737.
44. Lou, H., Kaur, K., Sharma, A.K., and Singal, P.K. 2006. Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes. Pathophysiology, 13(2): 103-109. doi:10.1016/j. pathophys.2006.02.004. PMID:16580821.
45. Lüthy, A., Furrer, M., Waser, M., Maggiorini, M., Pluess, H.J., Real, F., et al. 1992. Orthotopic heart transplantation: an efficient treatment in a young boy with doxorabicin-induced cardiomyopathy. J. Heart Lung Transplant. 11(4 Pt 1): 815-816. PMID:1323330.
46. Malcom, J., Arnold, O., Howlett, J.G., Ducharme, A., Ezekowitz, J.A., Gardner, M.J., et al. 2008. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure - 2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can. J. Cardiol. 24(1): 21-40. PMID:18209766.
47. Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., et al. 2005. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23(19): 4265-4274. doi:10.1200/JCO.2005.04.173. PMID:15911866.
48. Mason, J.W., Bristow, M.R., Billingham, M.E., and Daniels, J.R. 1978. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat. Rep. 62(6): 857-864. PMID:667859.
49. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2): 185-229. doi:10.1124/pr.56.2.6. PMID:15169927.
50. Mitra, M.S., Donthamsetty, S., White, B., Latendresse, J.R., and Mehendale, H.M. 2007. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol. Appl. Pharmacol. 225(1): 90-101. doi:10.1016/j.taap.2007.07.018. PMID:17904602.
51. Mitra, M.S., Donthamsetty, S., White, B., and Mehendale, H.M. 2008. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol. Appl. Pharmacol. 231(3): 413-422. doi:10.1016/j.taap. 2008.05.006. PMID:18674790.
52. Mizutani, H., Tada-Oikawa, S., Hiraku, Y., Kojima, M., and Kawanishi, S. 2005. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 76(13): 1439-1453. doi:10.1016/j.lfs.2004.05.040. PMID:15680309.
53. Pfeffer, M.A., Braunwald, E., Moyé, L.A., Basta, L., Brown, E.J., Jr., Cuddy, T.E., et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial - the SAVE investigators. N. Engl. J. Med. 327(10): 669-677. PMID:1386652.
54. Piedbois, P., Serin, D., Priou, F., Laplaige, P., Greget, S., Angellier, E., et al. 2007. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks-AERO B03 randomized phase II study. Ann. Oncol. 18(1): 52-57. doi:10.1093/annonc/mdl355. PMID:17047001.
55. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., et al.Randomized Aldactone Evaluation Study Investigators. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341(10): 709-717. doi:10.1056/NEJM199909023411001. PMID:10471456.
56. Praga, C., Beretta, G., Vigo, P.L., Lenaz, G.R., Pollini, C., Bonadonna, G., et al. 1979. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep. 63(5): 827-834. PMID:455324.
57. Quiles, J.L., Huertas, J.R., Battino, M., Mataix, J., and Ramírez-Tortosa, M.C. 2002. Antioxidant nutrients and adriamycin toxicity. Toxicology, 180(1): 79-95. doi:10.1016/S0300483X(02)00383-9. PMID:12324201.
58. Relling, M.V., and Dervieux, T. 2001. Pharmacogenetics and cancer therapy. Nat. Rev. Cancer, 1(2): 99-108. doi:10.1038/35101056. PMID:11905809.
59. Roché, H., Fumoleau, P., Spielmann, M., Canon, J.L., Delozier, T., Serin, D., et al. 2006. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J. Clin. Oncol. 24(36): 5664-5671. doi:10.1200/JCO.2006.07.3916. PMID:17116941.
60. Schuchter, L.M., Hensley, M.L., Meropol, N.J., and Winer, E.P.; American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 20(12): 2895-2903. doi:10.1200/JCO.2002.04.178. PMID:12065567.
61. Sengupta, S., Eavarone, D., Capila, T., Zhao, G., Watson, N., Kiziltepe, T., and Sasisekharan, R. 2005. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436(7050): 568-572. doi:10.1038/nature03794. PMID:16049491.
62. Singal, P.K., and Iliskovic, N. 1998. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339(13): 900-905. doi:10.1056/NEJM199809243391307. PMID:9744975.
63. Singal, P.K., Siveski-Iliskovic, N., Kaul, N., and Sahai, M. 1992. Significance of adaptation mechanisms in adriamycin induced congestive heart failure. Basic Res. Cardiol. 87(6): 512-518. doi:10.1007/BF00788661. PMID:1485884.
64. Singal, P.K., Iliskovic, N., Li, T., and Kumar, D. 1997. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11(12): 931-936. PMID:9337145.
65. Singal, P.K., Li, T., Kumar, D., Danelisen, I., and Iliskovic, N. 2000. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell. Biochem. 207(1-2): 77-86. doi:10.1023/A:1007094214460. PMID:10888230.
66. Siveski-Iliskovic, N., Kaul, N., and Singal, P.K. 1994. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation, 89(6): 2829-2835. PMID:8205698. (Pubitemid 24173705)
67. Siveski-Iliskovic, N., Hill, M., Chow, D.A., and Singal, P.K. 1995. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 91(1): 10-15. PMID:7805190.
68. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905): 707-712. doi:10.1126/science.2470152. PMID:2470152. (Pubitemid 19147683)
69. Takemura, G., and Fujiwara, H. 2007. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 49(5): 330-352. doi:10.1016/j.pcad.2006.10.002. PMID:17329180.
70. Tallaj, J.A., Franco, V., Rayburn, B.K., Pinderski, L., Benza, R.L., Pamboukian, S., et al. 2005. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J. Heart Lung Transplant. 24(12): 2196-2201. doi:10.1016/j.healun.2004.12.108. PMID:16364871. (Pubitemid 41814746)
71. van Dalen, E.C., Caron, H.N., Dickinson, H.O., and Kremer, L.C. 2008. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 2(2): CD003917. PMID:18425895.
72. Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Jr., Von Hoff, A.L., Rozencweig, M., and Muggia, F.M. 1979. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5): 710-717. PMID:496103.
73. Wang, S.C., Zhang, L., Hortobagyi, G.N., and Hung, M.C. 2001. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol. 28(6 Suppl 18): 21-29. doi:10.1053/sonc.2001.29724. PMID:11774202.
74. Weiss, R.B. 1992. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19(6): 670-686. PMID:1462166.
75. Yu, C.M., Sanderson, J.E., Marwick, T.H., and Oh, J.K. 2007. Tissue Doppler imaging: a new prognosticated for cardiovascular diseases. J. Am. Coll. Cardiol. 49(19): 1903-1914. doi:10.1016/j.jacc.2007.01.078. PMID:17498573.
76. Zancanella, P., Pianovski, M.A., Oliveira, B.H., Ferman, S., Piovezan, G.C., Lichtvan, L.L., et al. 2006. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J. Pediatr. Hematol. Oncol. 28(8): 513-524. doi:10.1097/01.mph.0000212965.52759.1c. PMID:16912591.